Global vaccine landscape...

 https://www.reuters.com/world/americas/cuba-encouraged-by-early-trials-homegrown-covid-19-vaccine-2021-06-20/

Cuban Soberana vaccine efficacy 62% (CI 40-84%) after 2 dosis, in 2 weeks we should know efficacy of 3 dosis possibly 70-80% and higher for severe cases and deaths.

Hope that data and GMPs allow for WHO emergency registration soon.

These results preclude a   vaccine landscape of two main groups :

1-Private/Commercial/against patent waiver and technology transfer/Genetic base + nanovector and high cold chain requirements (Pfeizer, Moderna, Janssen) with efficacy >90% for clinical cases yet ~50% for transmission and unknown mid-long term side effects.

1b- Private/Committed to price of production cost (yet no transparency, patent shield and no technology transfer)/Genetic base + viral vectors, and high cold chain requirements with 

Astra Zeneca, Sputnik* (*yet to be registered by WHO) 

with efficacy >60% for clinical cases yet ~50% for transmission /, cicwrn for short term clotting disorders and unknown mid-long term side effects.

2-Public/non-commercial /amenable to patent waiver and technology transfer/

Traditional means and low cold chain requirements (Chinese Sinopharm and Sinovac (inactivated COVID) and Cuban (protein + tetanos toxoid) with efficacy >60% for clinical cases  and no risk of mid-long term side effects.

2b: Novavax (registration 3Q by FDA and WHO), commercial/protein+nanovector/with efficacy >90% and no riskof mid-long term side effects... yet managed by US Department of Defense...

In summary, there may be Covid vaccines (requiring annual vaccinations except for natural immunity??) for the rich countries, rolled one year ahead and subject to patent and commercial interests > global good yet entering the unknown doorsteps of genetic-based-patent-pritecged medicine time...

vs.

vaccines for the poorer countries, registered later, of public source, open to technology transfer and with no private commercial interests > global good and safe of unknown long term side effects, amenable for child immunization programmes (Cuba could even go for a child hexavalent vaccine..)

Meanwhile, Covax, the WHO strategy for vaccine equity, is led by corporations and their philantropy of the first group and, without technology transfer, subject to inequity dynamics..

Challenging times ahead...